140 related articles for article (PubMed ID: 37678078)
1. Treatment strategies and drug resistance mechanisms in adenocarcinoma of different organs.
Xing P; Wang S; Cao Y; Liu B; Zheng F; Guo W; Huang J; Zhao Z; Yang Z; Lin X; Sang L; Liu Z
Drug Resist Updat; 2023 Nov; 71():101002. PubMed ID: 37678078
[TBL] [Abstract][Full Text] [Related]
2. Involucrin in well-differentiated adenocarcinoma of the lung. Comparison with adenocarcinomas of different organs.
Ando K; Kikuchi M; Eimoto T; Shirakusa T
Pathol Res Pract; 1991 Jan; 187(1):50-4. PubMed ID: 2027822
[TBL] [Abstract][Full Text] [Related]
3. Expression of the intestinal marker Cdx2 in secondary adenocarcinomas of the colorectum.
Groisman GM; Bernheim J; Halpern M; Brazowsky E; Meir A
Arch Pathol Lab Med; 2005 Jul; 129(7):920-3. PubMed ID: 15974817
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemistry of ductal adenocarcinoma of the prostate and adenocarcinomas of non-prostatic origin: a comparative study.
Seipel AH; Samaratunga H; Delahunt B; Wiklund P; Clements M; Egevad L
APMIS; 2016 Apr; 124(4):263-70. PubMed ID: 26778368
[TBL] [Abstract][Full Text] [Related]
5. Cigarette smoking and K-ras mutations in pancreas, lung and colorectal adenocarcinomas: etiopathogenic similarities, differences and paradoxes.
Porta M; Crous-Bou M; Wark PA; Vineis P; Real FX; Malats N; Kampman E
Mutat Res; 2009; 682(2-3):83-93. PubMed ID: 19651236
[TBL] [Abstract][Full Text] [Related]
6. Mucinous and secondary tumors of the prostate.
Osunkoya AO
Mod Pathol; 2018 Jan; 31(S1):S80-S95. PubMed ID: 29297488
[TBL] [Abstract][Full Text] [Related]
7. [New molecular classification of colorectal cancer, pancreatic cancer and stomach cancer: Towards "à la carte" treatment?].
Dreyer C; Afchain P; Trouilloud I; André T
Bull Cancer; 2016; 103(7-8):643-50. PubMed ID: 27345450
[TBL] [Abstract][Full Text] [Related]
8. Tumour expression of leptin is associated with chemotherapy resistance and therapy-independent prognosis in gastro-oesophageal adenocarcinomas.
Bain GH; Collie-Duguid E; Murray GI; Gilbert FJ; Denison A; McKiddie F; Ahearn T; Fleming I; Leeds J; Phull P; Park K; Nanthakumaran S; Matula KM; Grabsch HI; Tan P; Welch A; Schweiger L; Dahle-Smith A; Urquhart G; Finegan M; Petty RD
Br J Cancer; 2014 Mar; 110(6):1525-34. PubMed ID: 24569475
[TBL] [Abstract][Full Text] [Related]
9. Expression and localization of Reg IV in human neoplastic and non-neoplastic tissues: Reg IV expression is associated with intestinal and neuroendocrine differentiation in gastric adenocarcinoma.
Oue N; Mitani Y; Aung PP; Sakakura C; Takeshima Y; Kaneko M; Noguchi T; Nakayama H; Yasui W
J Pathol; 2005 Oct; 207(2):185-98. PubMed ID: 16086444
[TBL] [Abstract][Full Text] [Related]
10. APRIL is a novel clinical chemo-resistance biomarker in colorectal adenocarcinoma identified by gene expression profiling.
Petty RD; Samuel LM; Murray GI; MacDonald G; O'Kelly T; Loudon M; Binnie N; Aly E; McKinlay A; Wang W; Gilbert F; Semple S; Collie-Duguid ES
BMC Cancer; 2009 Dec; 9():434. PubMed ID: 20003335
[TBL] [Abstract][Full Text] [Related]
11. Regression of mouse prostatic intraepithelial neoplasia by nonsteroidal anti-inflammatory drugs in the transgenic adenocarcinoma mouse prostate model.
Narayanan BA; Narayanan NK; Pittman B; Reddy BS
Clin Cancer Res; 2004 Nov; 10(22):7727-37. PubMed ID: 15570007
[TBL] [Abstract][Full Text] [Related]
12. Mucin 16 (cancer antigen 125) expression in human tissues and cell lines and correlation with clinical outcome in adenocarcinomas of the pancreas, esophagus, stomach, and colon.
Streppel MM; Vincent A; Mukherjee R; Campbell NR; Chen SH; Konstantopoulos K; Goggins MG; Van Seuningen I; Maitra A; Montgomery EA
Hum Pathol; 2012 Oct; 43(10):1755-63. PubMed ID: 22542127
[TBL] [Abstract][Full Text] [Related]
13. miR-20a targets BNIP2 and contributes chemotherapeutic resistance in colorectal adenocarcinoma SW480 and SW620 cell lines.
Chai H; Liu M; Tian R; Li X; Tang H
Acta Biochim Biophys Sin (Shanghai); 2011 Mar; 43(3):217-25. PubMed ID: 21242194
[TBL] [Abstract][Full Text] [Related]
14. Effects of combination endocrine treatment on normal prostate, prostatic intraepithelial neoplasia, and prostatic adenocarcinoma.
Montironi R; Magi-Galluzzi C; Muzzonigro G; Prete E; Polito M; Fabris G
J Clin Pathol; 1994 Oct; 47(10):906-13. PubMed ID: 7525657
[TBL] [Abstract][Full Text] [Related]
15. Synchronous triple cancers of the pancreas, stomach, and cecum treated with S-1 followed by pancrelipase treatment of pancreatic exocrine insufficiency.
Ohtsubo K; Ishikawa D; Nanjo S; Takeuchi S; Yamada T; Mouri H; Yamashita K; Yasumoto K; Gabata T; Matsui O; Ikeda H; Takamatsu Y; Iwakami S; Yano S
JOP; 2013 Sep; 14(5):515-20. PubMed ID: 24018598
[TBL] [Abstract][Full Text] [Related]
16. Chemoradiation in pancreatic adenocarcinoma: a literature review.
Roy R; Maraveyas A
Oncologist; 2010; 15(3):259-69. PubMed ID: 20203172
[TBL] [Abstract][Full Text] [Related]
17. Lineage plasticity in cancer: a shared pathway of therapeutic resistance.
Quintanal-Villalonga Á; Chan JM; Yu HA; Pe'er D; Sawyers CL; Sen T; Rudin CM
Nat Rev Clin Oncol; 2020 Jun; 17(6):360-371. PubMed ID: 32152485
[TBL] [Abstract][Full Text] [Related]
18. Interaction network analysis of YBX1 for identification of therapeutic targets in adenocarcinomas.
Murugesan SN; Yadav BS; Maurya PK; Chaudhary A; Singh S; Mani A
J Biosci; 2019 Jun; 44(2):. PubMed ID: 31180040
[TBL] [Abstract][Full Text] [Related]
19. Biomarkers and pathways of chemoresistance and chemosensitivity for personalized treatment of pancreatic adenocarcinoma.
Zemanek T; Melichar B; Lovecek M; Soucek P; Mohelnikova-Duchonova B
Pharmacogenomics; 2019 Jan; 20(2):113-127. PubMed ID: 30539680
[TBL] [Abstract][Full Text] [Related]
20. The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma.
Spratlin J; Sangha R; Glubrecht D; Dabbagh L; Young JD; Dumontet C; Cass C; Lai R; Mackey JR
Clin Cancer Res; 2004 Oct; 10(20):6956-61. PubMed ID: 15501974
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
